PCM
ANIP icon

Price Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Price Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,809
Closed -$238K – 15
2015
Q1 		$238K Buy
+3,809
New +$232K 0.15% 168

Other funds holding ANIP

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
TCM
Timpani Capital Management Milwaukee, Wisconsin $209M AUM 62.15% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Price Capital Management's ANIP Position: Q2 2015 in Review

Price Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2015, closing a stake of 3,809 shares — an estimated $238K sold.

Price Capital Management first reported a position in ANIP in Q1 2015 and held it in 1 quarter. The position peaked at $238K in Q1 2015. 123 funds tracked by Wall St. Rank hold ANIP as of Q2 2015.

  • Price Capital Management reported no remaining ANI Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Price Capital Management sold 3,809 ANI Pharmaceuticals shares in Q2 2015, an estimated $238K.
  • Price Capital Management first reported a position in ANI Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Price Capital Management's ANI Pharmaceuticals position peaked at $238K in Q1 2015.
  • 123 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2015.

Based on Price Capital Management's 13F filing for Q2 2015.